Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors

By Kalmadi S.   Davis M.   Dowlati A.   O’Keefe S.   Cline-Burkhardt M.   Pelley R.   Borden E.   Dreicer R.   Bukowski R.   Mekhail T.  

Investigational New Drugs, Vol. 25, Iss. 3, 2007-06 ,pp. : 211-216

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of weekly docetaxel, weekly doxorubicin, daily oral cyclophosphamide, and G-CSF (ConTAC Regimen)in advanced malignancies

By Wesolowski Robert   Peereboom David   Weiss Patricia   Elson Paul   Thomas Budd George  

Investigational New Drugs, Vol. 28, Iss. 4, 2010-08 ,pp. : 502-508

Springer Publishing Company

Access to resources Recommend Favorite

Phase I Trial of Dose-Dense Docetaxel and Doxorubicin with or without Sargramostim in Patients with Metastatic Breast Cancer

By Montero Alberto   Booser Daniel   Esparza-Guerra Laura   Murray James   Rosales Marguerite   Hortobagyi Gabriel   Valero Vicente  

Drugs in R&D, Vol. 6, Iss. 5, 2005-01 ,pp. : 299-305

Adis International

Access to resources Recommend Favorite

Phase I/II trial of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC)

By Israel Valerie   Tagawa Scott   Snyder Terry   Jeffers Susan   Raghavan Derek  

Investigational New Drugs, Vol. 22, Iss. 3, 2004-08 ,pp. : 291-297

Springer Publishing Company

Access to resources Recommend Favorite

A phase I study of flavopiridol and docetaxel

By El-Rayes Basil   Gadgeel Shirish   Parchment Ralph   Lorusso Patricia   Philip Philip  

Investigational New Drugs, Vol. 24, Iss. 4, 2006-07 ,pp. : 305-310

Springer Publishing Company

Access to resources Recommend Favorite